Statin use reduces the risk of dementia in elderly patients: A nationwide data survey and propensity analysis

C. K. Wu, Y. H. Yang, T. T. Lin, C. T. Tsai, J. J. Hwang, J. L. Lin, P. C. Chen, F. T. Chiang, L. Y. Lin

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objectives: The objective of this study was to examine the association between the use of statins and the risk of newly diagnosed dementia in an elderly population. Design, setting and participants: Random samples of 1000 000 individuals covered by the National Health Insurance in Taiwan were included in the analysis. All participants were 65 years or older without dementia and either did or did not start treatment with statins from 1 August 1997 to 31 December 2010. Patients with established dementia before the start of treatment were excluded. Baseline characteristics were matched (by propensity score) in those who did and did not receive statins. Results: A total of 57 669 subjects were included in the analysis with approximately 12 years of follow-up. Propensity score matching identified 2003 patients who received statins and another 2003 patients who did not with comparable baseline characteristics. Adjusted hazard ratios (HRs) for dementia were significantly inversely associated with total or daily equivalent statin dosage (total accumulated dose: HRs 0.829, 0.720 and 0.385 from T1 to T3 vs. control, P < 0.001 for trend; mean daily dose: HRs 0.667, 0.798 and 0.503 from T1 to T3 vs. control, P < 0.001). The results remained robust after propensity adjustment. Conclusion: Independent of traditional risk factors, there was a decrease in newly diagnosed cases of dementia in elderly patients who had received a high total or daily dose of statins. The more potent statins (e.g. atorvastatin and rosuvastatin) seemed to be particularly effective in the prevention of dementia.

Original languageEnglish
Pages (from-to)343-352
Number of pages10
JournalJournal of Internal Medicine
Volume277
Issue number3
DOIs
Publication statusPublished - Mar 1 2015
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dementia
Propensity Score
Social Adjustment
National Health Programs
Surveys and Questionnaires
Taiwan
Therapeutics
Population

Keywords

  • Atorvastatin
  • Dementia
  • Propensity score
  • Rosuvastatin
  • Statins

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Statin use reduces the risk of dementia in elderly patients : A nationwide data survey and propensity analysis. / Wu, C. K.; Yang, Y. H.; Lin, T. T.; Tsai, C. T.; Hwang, J. J.; Lin, J. L.; Chen, P. C.; Chiang, F. T.; Lin, L. Y.

In: Journal of Internal Medicine, Vol. 277, No. 3, 01.03.2015, p. 343-352.

Research output: Contribution to journalArticle

Wu, CK, Yang, YH, Lin, TT, Tsai, CT, Hwang, JJ, Lin, JL, Chen, PC, Chiang, FT & Lin, LY 2015, 'Statin use reduces the risk of dementia in elderly patients: A nationwide data survey and propensity analysis', Journal of Internal Medicine, vol. 277, no. 3, pp. 343-352. https://doi.org/10.1111/joim.12262
Wu, C. K. ; Yang, Y. H. ; Lin, T. T. ; Tsai, C. T. ; Hwang, J. J. ; Lin, J. L. ; Chen, P. C. ; Chiang, F. T. ; Lin, L. Y. / Statin use reduces the risk of dementia in elderly patients : A nationwide data survey and propensity analysis. In: Journal of Internal Medicine. 2015 ; Vol. 277, No. 3. pp. 343-352.
@article{9f17d6ab74b1405199e6d6316df35f9f,
title = "Statin use reduces the risk of dementia in elderly patients: A nationwide data survey and propensity analysis",
abstract = "Objectives: The objective of this study was to examine the association between the use of statins and the risk of newly diagnosed dementia in an elderly population. Design, setting and participants: Random samples of 1000 000 individuals covered by the National Health Insurance in Taiwan were included in the analysis. All participants were 65 years or older without dementia and either did or did not start treatment with statins from 1 August 1997 to 31 December 2010. Patients with established dementia before the start of treatment were excluded. Baseline characteristics were matched (by propensity score) in those who did and did not receive statins. Results: A total of 57 669 subjects were included in the analysis with approximately 12 years of follow-up. Propensity score matching identified 2003 patients who received statins and another 2003 patients who did not with comparable baseline characteristics. Adjusted hazard ratios (HRs) for dementia were significantly inversely associated with total or daily equivalent statin dosage (total accumulated dose: HRs 0.829, 0.720 and 0.385 from T1 to T3 vs. control, P < 0.001 for trend; mean daily dose: HRs 0.667, 0.798 and 0.503 from T1 to T3 vs. control, P < 0.001). The results remained robust after propensity adjustment. Conclusion: Independent of traditional risk factors, there was a decrease in newly diagnosed cases of dementia in elderly patients who had received a high total or daily dose of statins. The more potent statins (e.g. atorvastatin and rosuvastatin) seemed to be particularly effective in the prevention of dementia.",
keywords = "Atorvastatin, Dementia, Propensity score, Rosuvastatin, Statins, Atorvastatin, Dementia, Propensity score, Rosuvastatin, Statins",
author = "Wu, {C. K.} and Yang, {Y. H.} and Lin, {T. T.} and Tsai, {C. T.} and Hwang, {J. J.} and Lin, {J. L.} and Chen, {P. C.} and Chiang, {F. T.} and Lin, {L. Y.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/joim.12262",
language = "English",
volume = "277",
pages = "343--352",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Statin use reduces the risk of dementia in elderly patients

T2 - A nationwide data survey and propensity analysis

AU - Wu, C. K.

AU - Yang, Y. H.

AU - Lin, T. T.

AU - Tsai, C. T.

AU - Hwang, J. J.

AU - Lin, J. L.

AU - Chen, P. C.

AU - Chiang, F. T.

AU - Lin, L. Y.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Objectives: The objective of this study was to examine the association between the use of statins and the risk of newly diagnosed dementia in an elderly population. Design, setting and participants: Random samples of 1000 000 individuals covered by the National Health Insurance in Taiwan were included in the analysis. All participants were 65 years or older without dementia and either did or did not start treatment with statins from 1 August 1997 to 31 December 2010. Patients with established dementia before the start of treatment were excluded. Baseline characteristics were matched (by propensity score) in those who did and did not receive statins. Results: A total of 57 669 subjects were included in the analysis with approximately 12 years of follow-up. Propensity score matching identified 2003 patients who received statins and another 2003 patients who did not with comparable baseline characteristics. Adjusted hazard ratios (HRs) for dementia were significantly inversely associated with total or daily equivalent statin dosage (total accumulated dose: HRs 0.829, 0.720 and 0.385 from T1 to T3 vs. control, P < 0.001 for trend; mean daily dose: HRs 0.667, 0.798 and 0.503 from T1 to T3 vs. control, P < 0.001). The results remained robust after propensity adjustment. Conclusion: Independent of traditional risk factors, there was a decrease in newly diagnosed cases of dementia in elderly patients who had received a high total or daily dose of statins. The more potent statins (e.g. atorvastatin and rosuvastatin) seemed to be particularly effective in the prevention of dementia.

AB - Objectives: The objective of this study was to examine the association between the use of statins and the risk of newly diagnosed dementia in an elderly population. Design, setting and participants: Random samples of 1000 000 individuals covered by the National Health Insurance in Taiwan were included in the analysis. All participants were 65 years or older without dementia and either did or did not start treatment with statins from 1 August 1997 to 31 December 2010. Patients with established dementia before the start of treatment were excluded. Baseline characteristics were matched (by propensity score) in those who did and did not receive statins. Results: A total of 57 669 subjects were included in the analysis with approximately 12 years of follow-up. Propensity score matching identified 2003 patients who received statins and another 2003 patients who did not with comparable baseline characteristics. Adjusted hazard ratios (HRs) for dementia were significantly inversely associated with total or daily equivalent statin dosage (total accumulated dose: HRs 0.829, 0.720 and 0.385 from T1 to T3 vs. control, P < 0.001 for trend; mean daily dose: HRs 0.667, 0.798 and 0.503 from T1 to T3 vs. control, P < 0.001). The results remained robust after propensity adjustment. Conclusion: Independent of traditional risk factors, there was a decrease in newly diagnosed cases of dementia in elderly patients who had received a high total or daily dose of statins. The more potent statins (e.g. atorvastatin and rosuvastatin) seemed to be particularly effective in the prevention of dementia.

KW - Atorvastatin

KW - Dementia

KW - Propensity score

KW - Rosuvastatin

KW - Statins

KW - Atorvastatin

KW - Dementia

KW - Propensity score

KW - Rosuvastatin

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84927172893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927172893&partnerID=8YFLogxK

U2 - 10.1111/joim.12262

DO - 10.1111/joim.12262

M3 - Article

C2 - 24766342

AN - SCOPUS:84927172893

VL - 277

SP - 343

EP - 352

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 3

ER -